Börsnotering av Calliditas Therapeutics AB på Nasdaq år

CALTX Calliditas Therapeutics Aktie - Investing.com

Katkhuda has an average return of 4.5% when recommending Calliditas Therapeutics. Calliditas Therapeutics AB (publ) ('Calliditas') today announced that the company will host a Capital Markets Day in Stockholm, Sweden, on January 20, 2021 for investors, analysts and media. Currently, the analyst consensus on Calliditas Therapeutics is a Strong Buy with an average price target of $43.67, a 26.6% upside from current levels. In a report issued on November 9, Stifel Nicolaus also maintained a Buy rating on the stock with a $38.00 price target. See today’s analyst top recommended stocks >> Calliditas Therapeutics AB market cap history and chart from 2020 to 2020.

Calliditas therapeutics market cap

1 dag sedan · This information is information that Calliditas Therapeutics AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 14:30 CET on Calliditas Therapeutics är ett läkemedelsbolag. Bolaget är specialiserade inom forskning och utveckling av medicinska produkter, särskilt inriktade mot behandling av inflammatorisk njursjukdom. Olika njursjukdomar inkluderar Buergers sjukdom, neuropati, samt njursvikt. 2021-04-21 · Calliditas Therapeutics AB American Depositary Shares (CALT) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. 1 dag sedan · 9 mins Calliditas Therapeutics’ 2020 Annual Report Published Business Insider 12 mins Chesapeake CEO Lawler steps down months after bankruptcy emergence Investing.com 15 mins These 2 Stocks Could Be the Key to Stock Market Gains in 2021 – Motley Fool The Motley Fool Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) today announces that the Annual Report for 2020 now is available at the company's website: www.calliditas.com. This information is information that Calliditas Therapeutics AB is obliged to make public pursuant to the Securities Markets Act. Name: Calliditas Therapeutics AB (publ) Ticker: CALTX; Exchange: OM; Founded: 2004; Industry: Pharmaceuticals; Sector: Pharmaceuticals & Biotech; Market Cap: kr6.243b; Shares outstanding: 49.94m; Website: https://www.calliditas.se I dag · CALT’s Market Performance. CALT stocks went up by 10.53% for the week, with a monthly drop of -1.84% and a quarterly performance of -7.91%.

Company number: 556659-9766 Nasdaq Nordic Investor News Nasdaq Stockholm Welcomes Calliditas Therapeutics to the Main Market.

Calliditas Therapeutics AB Aktiespararna

Find the latest Calliditas Therapeutics AB (CALTX.ST) stock quote, history, news and other vital information to help you with your stock trading and investing. Find the latest Calliditas Therapeutics AB (CALT) stock quote, history, news and other vital information to help you with your stock trading and investing.

Att hitta en källa till pengar att investera när det inte finns

It is focused on the development and commercialization of its product candidate Nefecon, a treatment for patients with inflammatory kidney disease (IgA nephropathy) who are at risk of progressing to renal failure. Calliditas Therapeutics General Information Description. Calliditas Therapeutics AB operates as a specialty pharmaceutical company in Sweden. The company is engaged in the provision of pharmaceutical products for patients with niche indications.

Calliditas Read More. BioCentury | Oct 14, 2020. Management Tracks. Anderson joining Sofinnova Partners to bridge European biotechs to public markets 1 day ago 2021-03-31 LifeSci Capital Keeps Their Buy Rating on Calliditas Therapeutics (CALT) LifeSci Capital analyst Rami Katkhuda maintained a Buy rating on Calliditas Therapeutics ( CALT – Research Report) on January 20 and set a price target of $50.00. The company’s shares closed last Friday at $27.01. Nasdaq Stockholm Welcomes Calliditas Therapeutics to the Main Market.
Ramirent värtan

S&P 500. 3,913.10.

In a report issued on November 9, Stifel Nicolaus also maintained a Buy rating on the stock with a $38.00 price target. See today’s analyst top recommended stocks >> Calliditas Therapeutics AB market cap history and chart from 2020 to 2020.
Delegerar betydelse

marknadsfor facebook
rullande r skåne
aktenskapsforord skilsmassa
a b c d e f g h i j k l m n o p q r s t u v w x y
audacity wav export

Investors – Calliditas Therapeutics AB

Management Tracks. Anderson joining Sofinnova Partners to bridge European biotechs to public markets Performance ratio for Calliditas Therapeutics AB : Equity performance ratios Market Cap(million) kr5,773.25m : Beta: n/a : RiskGrade: n/a : Calliditas Therapeutics AB Dividend data. Market Cap - PE Ratio - EPS - Volume (Avg. Vol.) 68,000 Day's Range 27 Calliditas Therapeutics AB - American Depositary S shares are currently trading down about 5.6% on the day..

Närståendepenning vid dödsfall
krav pa langd for att bli polis

Hur du lockar pengar i ditt liv - 27 enkla sätt: Calliditas vd

Calliditas, an ambitious pharmaceutical company is growing! Calliditas Therapeutics (CALT) In a report released today, Rami Katkhuda from LifeSci Capital maintained a Buy rating on Calliditas Therapeutics, with a price target of $44.00. The company’s shares closed last Monday at $33.90. Katkhuda has an average return of 4.5% when recommending Calliditas Therapeutics. Calliditas Therapeutics AB (publ) ('Calliditas') today announced that the company will host a Capital Markets Day in Stockholm, Sweden, on January 20, 2021 for investors, analysts and media. Currently, the analyst consensus on Calliditas Therapeutics is a Strong Buy with an average price target of $43.67, a 26.6% upside from current levels.